NEUROSENSE THERAPEUTICS LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.26 USD | -5.97% |
|
-17.11% | +60.51% |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
Calendar
2024-05-28
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.26
USD
Average target price
5.25
USD
Spread / Average Target
+316.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +60.51% | 21.84M | |
| -2.26% | 103B | |
| +1.41% | 95.71B | |
| +0.93% | 22.02B | |
| -17.84% | 20.9B | |
| -9.12% | 17.85B | |
| -42.83% | 16.21B | |
| -17.63% | 15.52B | |
| +4.55% | 13.86B | |
| +32.11% | 12.04B |
- Stock Market
- Equities
- NRSN Stock
- News NeuroSense Therapeutics Ltd.
- Sector Update: Health Care Stocks Slip Monday Afternoon
